GLP-1 medications are FDA-approved specifically for weight loss for more than half the adult population of the United States. Plan sponsors can take action to manage weight and other cardiodiabesity-related health challenges within their member population.

A report from the Evernorth Research Institute offers insights that can help health plans optimize cancer care.

To create a strong pipeline of early career technology talent, and create equitable opportunities for underrepresented students, Evernorth has partnered with Access Point – a program designed to provide accelerated hands-on technical training and mentorship.

We are taking a thoughtful and comprehensive approach to assessing biosimilar options that considers several factors.